Ghent University Academic Bibliography

Advanced

Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

Bieke Lambert UGent, EMIEL STURM UGent, Jeroen Mertens UGent, Ruth Oltenfreiter UGent, Peter Smeets UGent, Roberto Troisi UGent, Hans Van Vlierberghe UGent and Luc Defreyne UGent (2011) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 38(12). p.2117-2124
abstract
Purpose We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with (90)Y microspheres. Secondly, we investigated the urinary excretion of (90)Y following treatment. Methods We retrospectively reviewed all HCC patients referred to our department for (90)Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Results Forty-three HCC patients were referred for radio-embolization. Fourteen patients were excluded, mainly due to unfavourable (99m)Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with (90)Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Conclusion Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of (90)Y excreted in the urine.
Please use this url to cite or link to this publication:
author
organization
alternative title
Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma : 4 years experience at the Ghent University Hospital
year
type
journalArticle (original)
publication status
published
subject
keyword
Liver, Microspheres, Hepatocellular carcinoma (HCC), Selective internal radiation therapy (SIRT), (90)Y, LIVER-TRANSPLANTATION, RADIOEMBOLIZATION, CHEMOEMBOLIZATION, MANAGEMENT, OUTCOMES, SAFETY
journal title
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Eur. J. Nucl. Med. Mol. Imaging
volume
38
issue
12
pages
2117 - 2124
Web of Science type
Article
Web of Science id
000297732700003
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
4.991 (2011)
JCR rank
8/116 (2011)
JCR quartile
1 (2011)
ISSN
1619-7070
DOI
10.1007/s00259-011-1881-2
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1976309
handle
http://hdl.handle.net/1854/LU-1976309
date created
2012-01-01 11:04:28
date last changed
2012-01-05 10:18:49
@article{1976309,
  abstract     = {Purpose We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with (90)Y microspheres. Secondly, we investigated the urinary excretion of (90)Y following treatment. 
Methods We retrospectively reviewed all HCC patients referred to our department for (90)Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. 
Results Forty-three HCC patients were referred for radio-embolization. Fourteen patients were excluded, mainly due to unfavourable (99m)Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with (90)Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15\%, partial response in 35\%, stable disease in 30\% and progression in 20\% were observed. A median survival of 12.3 months (95\% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025\% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. 
Conclusion Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50\%, when evaluated early following treatment. Urine analysis showed consistently only low activities of (90)Y excreted in the urine.},
  author       = {Lambert, Bieke and STURM, EMIEL and Mertens, Jeroen and Oltenfreiter, Ruth and Smeets, Peter and Troisi, Roberto and Van Vlierberghe, Hans and Defreyne, Luc},
  issn         = {1619-7070},
  journal      = {EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
  keyword      = {Liver,Microspheres,Hepatocellular carcinoma (HCC),Selective internal radiation therapy (SIRT),(90)Y,LIVER-TRANSPLANTATION,RADIOEMBOLIZATION,CHEMOEMBOLIZATION,MANAGEMENT,OUTCOMES,SAFETY},
  language     = {eng},
  number       = {12},
  pages        = {2117--2124},
  title        = {Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital},
  url          = {http://dx.doi.org/10.1007/s00259-011-1881-2},
  volume       = {38},
  year         = {2011},
}

Chicago
Lambert, Bieke, EMIEL STURM, Jeroen Mertens, RUTH OLTENFREITER, Peter Smeets, Roberto Troisi, Hans Van Vlierberghe, and Luc Defreyne. 2011. “Intra-arterial Treatment with 90Y Microspheres for Hepatocellular Carcinoma: 4 Years Experience at the Ghent University Hospital.” European Journal of Nuclear Medicine and Molecular Imaging 38 (12): 2117–2124.
APA
Lambert, Bieke, STURM, E., Mertens, J., OLTENFREITER, R., Smeets, P., Troisi, R., Van Vlierberghe, H., et al. (2011). Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 38(12), 2117–2124.
Vancouver
1.
Lambert B, STURM E, Mertens J, OLTENFREITER R, Smeets P, Troisi R, et al. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38(12):2117–24.
MLA
Lambert, Bieke, EMIEL STURM, Jeroen Mertens, et al. “Intra-arterial Treatment with 90Y Microspheres for Hepatocellular Carcinoma: 4 Years Experience at the Ghent University Hospital.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38.12 (2011): 2117–2124. Print.